Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Published byYanti Cahyadi Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors."— Presentation transcript:

1 Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. (A) In vivo bioluminescence imaging of the B16F10 tumor growth in C57B6 mice after various treatments as indicated. (B to D) Individual (B) and average quantitative bioluminescence signals of tumors (C) and tumor growth kinetics (D) in control and treated groups. Black arrows indicate the day of the surgery (day 9). (E) Survival curves for different treatments (n = 7 to 10). Growth curves were stopped when the first animal of the corresponding group was euthanized. Data are means ± SEM. Statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < Chao Wang et al., Sci Transl Med 2018;10:eaan3682 Published by AAAS

Download ppt "Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors."

Similar presentations

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.
Body weight at harvest (g) Left kidney:body weight ratio (g/kg)

Body weight at harvest (g) Left kidney:body weight ratio (g/kg)
Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.
Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.

Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.
In vivo selectivity of compound 6b.

In vivo selectivity of compound 6b.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.

Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.
Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.
Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions
MRSA virulence proteins cause LMC death and diminished CLV function

MRSA virulence proteins cause LMC death and diminished CLV function
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Similar presentations

Ads by Google